New Hampshire is facing a growing number of Hepatitis C incidences relating to the state’s recent opioid outbreak. The practice of sharing needles among intravenous drug users has led many providers in the state, including gastroenterologists, to see a larger than normal number of cases of Hepatitis C, bacterial endocarditis and other severe infections among this population. Hepatitis C is a curable disease and treatments can cost up to $100,000 per patient. Due to the prevention possibilities regarding Hepatitis C and its potential correlation with HIV among drug users, New Hampshire officials are considering steps to assist this group with treatment.
